

Index

A

Aberrant epigenetic changes, 77
Alkylating agents, 125
Alkylphosphocholine analogs, 3, 6
Amino acids, 3, 8
Angiogenesis, 138
Antimetabolites, 125
Apoptosis, 149, 163
Apoptosis-induced proliferation, 150
Artificial DDR, 126
Ascites in metastasis, 85

B

Baseline assessment, 22
Blue cell tumor, 183
Bone marrow, 110
Bone metastasis, 109
Brain metastases, 1

C

Cancer metastasis, 117
Cancer metastatic predisposition, 119
Cancer progression, 143
Cancer stages, 64
Cancer staging, 25
Capnothorax, 42
Caspases, 152
CD99, 184
Cell death, 166
Cell signaling, 185
Chemotherapy resistance, 163

Chromosomal abnormality, 141
Clinical evidence, 120
Clinical implications, 117
Clinical presentation, 81
Computed tomography, 1
Copenhagen anterior approach, 39
Cytoreductive surgery, 79

D

DDR inhibitors, 126, 128
Diagnosis and management, 17
Diagnostic strategies, 21
DNA damage repair, 165
DNA damage response, 117
Drug metabolism, 165
Drug resistance, 142

E

Edinburgh posterior approach, 39
Efflux mechanisms, 164
Electron microscopy features, 182
Endometrial cancer, 66
Endoplasmic reticulum, 171
Endothelial cells, 137
Epigenetic regulation, 165
Epigenetics, 82
Epithelial ovarian cancer, 81
Epithelial-mesenchymal transition, 84, 92
Evolutionary model, 70
Ewing Sarcoma, 181
Extrinsic pathway, 151, 166

F

Female reproductive system, 64, 65
Fluorine 18, 10
Fluorodeoxyglucose, 4
Functional status, 2

G

Gene alterations, 119
Genomic landscapes, 63
Genomic profiling, 65, 69
Genotoxic, 125
Glucose analogs, 3, 4
Glycogen deposits, 184
Gonzales-Rivas approach, 40
Gynecological cancers, 63

H

Hematological toxicity, 109
Histological type, 55
Histopathology, 20
Hormones, 20
Human genome, 118
Hypermutation phenotype, 122

I

Imaging tests, 17
Immune-checkpoint inhibitor, 127
Independent primary synchronous cancers, 72
Indocyanine green, 57
Inhibitors of apoptosis, 169
Integrins, 86
Intercostal incision, 37
Intracranial neoplasms, 2
Intrinsic pathway of apoptosis, 152

Intrinsic pathway, 167
Ionizing radiation, 125

J

Jag-1, 143
JAK/STAT3, 96
Japan, 53
JNK signaling, 153

K

Karnovsky osmium tetroxide-potassium
ferricyanide fixative, 183

L

Lateral thoracotomies, 37
Light microscopy features, 182
Lobectomy, 36, 41
Lung cancer, 19, 33
Lung metastases, 50
Lung nodules, 17, 21
Lymph node metastasis, 68
Lymph node sampling, 35
Lymphadenectomy, 35, 54

M

Magnetic resonance imaging, 2
Massive parallel sequencing, 65
MetastamiRs, 91
Metastasectomy, 50
Metastases in gynecological cancers, 68
Metastasis, 51
Metastatic Ewing Sarcoma, 181
Metastatic gynecological cancers, 63
Metastatic phenotype, 91
Metastatic predisposition, 119

Metastatic site, 85
MicroRNAs, 91, 92
Mini-invasive surgery, 51
Mitochondria, 171
Mitogenic effect, 154
Molecular imaging, 1, 4
Monophyly, 70
Mullerian epithelium, 65
Mutator phenotype hypothesis, 119

N

Natural compounds, 171
Next generation sequencing, 65
Non-protein coding RNAs, 170
Non-small cell lung cancer, 34

O

Omental tumor microenvironment, 83
Oncogenetic origins, 185
Open surgery, 36
Origin of ovarian cancer, 80
Ovarian cancer, 65, 77
Overdiagnosis, 21

P

PARP inhibitor, 126
Patient communication, 27
Patterns of metastatic spread, 187
Patterns of spread, 68
Periodic Acid Schiff, 182
PET, 1
Phylogenetic models, 72
Phylogenies, 69
Platinum, 125
Pneumonectomy, 51
Positron emission tomography, 1, 2

Posterolateral thoracotomy, 36
Pre-clinical evidence, 119
Primitive neuroectodermal
tumor, 182
Proangiogenic phenotype, 139
Proliferation, 149
Prostate cancer, 91
Prostate specific membrane antigen
ligands, 3, 6
Pulmonary metastasectomy, 50
Pulmonary metastases, 49
Pulmonary nodules, 18

Q

Quantitative measurements, 1

R

Radiation therapy, 109
Re-do surgery, 56
Resection, 34
Rib-spreading thoracotomy, 36
Robotic-assisted
thoracoscopic surgery, 34, 41

S

Segmentectomy, 51
Site of origin, 80
Small cell lung cancer, 34
Smoking, 19
Spheroid formation, 84
Stages of ovarian cancer, 79
Stem-like phenotype, 141
Surgery, 34
Surgical indications, 49
Surgical margin, 53
Surgical principles, 49

Surveillance, 24, 25
Survival, 64
Synchronous endometrial and ovarian
 lesions, 70
Synthetic lethality, 126

T

Targeted sequencing, 65
Therapeutic challenges, 187
Therapeutic opportunities, 117
Thoracic surgery, 33, 50, 57
Thoracotomy, 34, 37, 51
Topoisomerase inhibitors, 125
Treating lung cancer, 33
Treatment resistance, 123
Treatment response, 25
Tumor blood vessels, 138, 139
Tumor endothelial cells, 137
Tumor evolution, 63, 69
Tumor genomic evolution, 122
Tumor immunogenicity, 127
Tumor microenvironment,
 77, 83, 122
Tumor monitoring, 11
Tumor progression, 121

U

Uptake mechanisms, 164

Urokinase plasminogen activator, 185
uPA/uPAR

V

V(D)J, 122
Vascular endothelial growth factor, 138
Video-assisted thoracoscopic
 surgery, 34, 38

W

Wedge resection, 35, 51
Whole-exome sequencing, 65
Whole-genome sequencing, 65
WNT-beta family, 154

X

Xenograft models, 120
Xerostomia, 157
XIAP-associated factor 1, 169

Y

Young adults, 182

Z

ZEB, 96
Zebrafish, 155